ArticleBMC immunology2026
Clinical significance of miR-548a-3p and its potential role in acute respiratory distress syndrome complicated with pulmonary fibrosis via OSM.
Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAcute respiratory distress syndrome (ARDS) is characterized by acute diffuse lung injury, with pulmonary fibrosis (PF) being a significant complication. The expression patterns and functional role of miR-548a-3p in ARDS and associated PF remain unexplored. PURPOSE: This study aims to delineate the diagnostic and prognostic significance of miR-548a-3p in ARDS and elucidate its underlying molecular mechanisms.
methodsSerum miR-548a-3p levels in ARDS patients were quantified using reverse transcription quantitative polymerase chain reaction (RT-qPCR). Diagnostic value was evaluated via receiver operating characteristic (ROC) curves and binary logistic regression, and prognostic significance via Kaplan-Meier analysis and Cox regression. Interleukin-6 (IL-6)/Interleukin-8 (IL-8) levels were measured via enzyme-linked immunosorbent assay (ELISA). Potential targets were screened (NCBI/miRDB) and binding validated by dual-luciferase reporter assays. In lipopolysaccharide (LPS)-injured BEAS-2B cells, miR-548a-3p/Oncostatin M (OSM) regulation effects were examined via ELISA, Cell Counting kit-8 (CCK-8), and flow cytometry.
resultsARDS patients exhibited decreased miR-548a-3p expression, which correlated negatively with IL-6 and IL-8. Furthermore, miR-548a-3p effectively discriminated between ARDS patients and healthy individuals and served as a predictor of ARDS. In LPS-injured BEAS-2B cells, miR-548a-3p overexpression promoted proliferation, suppressed apoptosis, and reduced inflammation. OSM was identified as a direct target of miR-548a-3p through database screening and experimental validation. OSM overexpression reversed the protective effects of miR-548a-3p on LPS-injured lung epithelial cells.
conclusionsThis study is the first to reveal that miR-548a-3p exerts protective effects in ARDS by targeting OSM, underscoring its great potential as a novel diagnostic and prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.